Hospital
Warren Memorial Hospital, INC.
Warren Memorial Hospital, INC. was paid $23.54M by Medicaid between Jan 2018 and Dec 2024, across 222 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoWARREN MEMORIAL HOSPITAL, INC.
FRONT ROYAL, VA 22630
FRONT ROYAL, VA 22630
33aNPI1427085232assigned 06/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.54M
24GClaims515,454
24DCodes billed222
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#30 of 80
Median peer was paid$14.69M
This provider vs. median1.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CHAMBERS, JILL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 56,001 | $1.78M | |
| 2019 | 69,809 | $2.60M | |
| 2020 | 63,504 | $2.68M | |
| 2021 | 79,123 | $3.36M | |
| 2022 | 78,179 | $3.86M | |
| 2023 | 92,717 | $4.61M | |
| 2024incomplete | 76,121 | $4.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 19,746 | 17,620 | $3.48M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 17,017 | 14,843 | $3.25M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10.0% | 12,218 | 10,843 | $2.35M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.0% | 8,556 | 7,000 | $2.11M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.9% | 28,584 | 6,775 | $1.61M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 6.0% | 16,466 | 3,338 | $1.41M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.2% | 3,438 | 3,205 | $983K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.0% | 13,401 | 3,810 | $698K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 3,645 | 3,289 | $658K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 4,369 | 3,607 | $601K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 3,447 | 3,209 | $544K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.0% | 2,743 | 2,537 | $466K |
210 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.9% | 7,118 | $455K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.9% | 1,758 | $450K |
| G0378 | Hospital observation service, per hour | 1.6% | 2,749 | $385K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.1% | 9,651 | $258K |
| 97161 | 1.0% | 1,706 | $237K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.0% | 5,435 | $236K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,478 | $229K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 634 | $226K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 904 | $215K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 755 | $187K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 697 | $186K |
| 76830 | Ultrasound, transvaginal | <1% | 1,391 | $178K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,527 | $135K |
| 80053 | Comprehensive metabolic panel | <1% | 26,720 | $123K |
| 97162 | <1% | 1,062 | $116K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 31,967 | $90K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 845 | $89K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,290 | $83K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,206 | $72K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,744 | $70K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,635 | $61K |
| 93971 | <1% | 459 | $50K | |
| 87428 | <1% | 2,820 | $47K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,747 | $46K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 309 | $45K |
| 81025 | <1% | 4,656 | $45K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 133 | $44K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,081 | $37K |
| 97010 | <1% | 1,660 | $37K | |
| 73564 | <1% | 1,472 | $34K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,270 | $33K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 143 | $32K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 567 | $32K |
| 97166 | <1% | 178 | $30K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,804 | $29K |
| 83880 | <1% | 2,372 | $26K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,113 | $24K |
| 73030 | <1% | 1,141 | $24K | |
| 92557 | <1% | 199 | $24K | |
| 73502 | <1% | 743 | $23K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,950 | $22K |
| 73110 | <1% | 710 | $21K | |
| 76536 | <1% | 168 | $19K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 195 | $19K |
| 92523 | <1% | 71 | $18K | |
| 73610 | <1% | 724 | $17K | |
| 80061 | Lipid panel | <1% | 2,060 | $16K |
| 74018 | <1% | 501 | $16K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 673 | $15K |
| 71271 | <1% | 124 | $15K | |
| 84484 | <1% | 9,697 | $14K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 567 | $14K |
| 71250 | <1% | 209 | $14K | |
| 87040 | <1% | 1,855 | $14K | |
| 73630 | <1% | 920 | $14K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,853 | $14K |
| 85379 | <1% | 2,164 | $13K | |
| 97026 | <1% | 569 | $13K | |
| 76770 | <1% | 97 | $13K | |
| 87077 | <1% | 926 | $11K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 745 | $11K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 13 | $11K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 495 | $11K |
| 73130 | <1% | 673 | $11K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,431 | $10K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 221 | $10K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 40 | $10K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,861 | $10K |
| 76801 | <1% | 150 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,938 | $9K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 968 | $8K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 38 | $8K |
| 84145 | <1% | 990 | $8K | |
| 72110 | <1% | 310 | $8K | |
| 96376 | <1% | 3,201 | $7K | |
| 85610 | <1% | 4,419 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,234 | $6K |
| 80143 | <1% | 1,384 | $6K | |
| 87420 | <1% | 265 | $5K | |
| J3490 | Unclassified drugs | <1% | 8,168 | $5K |
| 83655 | <1% | 380 | $5K | |
| 72100 | <1% | 165 | $5K | |
| 85018 | <1% | 948 | $5K | |
| 97165 | <1% | 53 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,663 | $4K |
| 97116 | <1% | 559 | $4K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,467 | $4K |
| 87634 | <1% | 315 | $4K | |
| 81001 | <1% | 8,706 | $4K | |
| 93017 | <1% | 41 | $4K | |
| 96367 | <1% | 77 | $4K | |
| 73562 | <1% | 100 | $4K | |
| 80306 | <1% | 4,358 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,920 | $3K |
| 81003 | <1% | 6,020 | $3K | |
| 73221 | <1% | 13 | $3K | |
| 80179 | <1% | 1,321 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 326 | $3K |
| 12001 | <1% | 14 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 168 | $3K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 37 | $3K |
| 87807 | <1% | 399 | $3K | |
| 86901 | <1% | 359 | $3K | |
| 94664 | <1% | 1,752 | $3K | |
| 81002 | <1% | 825 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,706 | $2K |
| 72141 | <1% | 14 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 31 | $2K |
| 93970 | <1% | 13 | $2K | |
| 87070 | <1% | 542 | $2K | |
| 70486 | <1% | 39 | $2K | |
| 83735 | <1% | 4,606 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 13 | $2K |
| 83605 | <1% | 1,725 | $2K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 38 | $2K |
| 97163 | <1% | 29 | $2K | |
| 82607 | <1% | 301 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 107 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,189 | $2K |
| 84703 | <1% | 2,905 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 216 | $2K |
| 82948 | <1% | 14,647 | $2K | |
| 87081 | <1% | 3,629 | $1K | |
| 86140 | <1% | 1,268 | $1K | |
| 82570 | <1% | 262 | $1K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 214 | $1K |
| 83690 | <1% | 5,193 | $1K | |
| 73080 | <1% | 68 | $1K | |
| 82746 | <1% | 198 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,984 | $948.20 |
| 36600 | <1% | 665 | $896.93 | |
| 82947 | <1% | 1,012 | $866.07 | |
| 80305 | <1% | 53 | $806.12 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 538 | $788.18 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 144 | $775.01 |
| 72050 | <1% | 40 | $765.32 | |
| 82728 | <1% | 157 | $730.51 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,402 | $701.03 |
| 87186 | <1% | 1,675 | $663.16 | |
| 86850 | <1% | 352 | $662.25 | |
| 85730 | <1% | 1,820 | $644.94 | |
| 73140 | <1% | 26 | $528.50 | |
| 85652 | <1% | 561 | $502.03 | |
| 87400 | <1% | 64 | $489.30 | |
| 97014 | <1% | 31 | $485.41 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 676 | $464.09 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,211 | $443.72 |
| 82803 | <1% | 898 | $391.58 | |
| 85027 | <1% | 150 | $341.54 | |
| 84702 | <1% | 237 | $314.56 | |
| 84466 | <1% | 70 | $305.99 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,797 | $277.29 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 448 | $261.27 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 563 | $231.05 |
| 94760 | <1% | 1,847 | $227.98 | |
| 93000 | <1% | 104 | $224.75 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,513 | $211.72 |
| 83540 | <1% | 86 | $203.24 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,506 | $155.67 |
| 84439 | <1% | 40 | $151.93 | |
| 84100 | <1% | 361 | $137.89 | |
| 74019 | <1% | 26 | $136.34 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 96 | $108.07 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 891 | $99.86 |
| 86900 | <1% | 359 | $94.28 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 861 | $89.18 |
| 71101 | <1% | 28 | $80.14 | |
| 87205 | <1% | 399 | $75.30 | |
| 73600 | <1% | 43 | $75.26 | |
| 80164 | <1% | 19 | $64.49 | |
| 82565 | <1% | 35 | $57.13 | |
| 82270 | <1% | 116 | $49.17 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 247 | $38.88 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 621 | $36.42 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 640 | $36.22 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 252 | $28.10 |
| 87210 | <1% | 15 | $26.61 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 228 | $22.73 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 413 | $20.62 |
| 88304 | <1% | 54 | $14.77 | |
| 82010 | <1% | 73 | $11.12 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 73 | $7.92 |
| 82550 | <1% | 118 | $6.16 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 59 | $5.03 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 43 | $3.84 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 16 | $3.12 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 47 | $0.69 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 336 | $0.57 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 31 | $0.41 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 47 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 117 | $0.00 |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 30 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 66 | $0.00 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 69 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 15 | $0.00 |
| 94761 | 0% | 33 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 18 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 13 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 159 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 80 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 113 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 25 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 65 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 48 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 28 | $0.00 |
| 73590 | 0% | 13 | $0.00 | |
| 29125 | 0% | 15 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 12 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 16 | $0.00 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHAMBERS, JILL (MGR INS CREDENTIALING)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.